Company profile: Psyence Biomed
1.1 - Company Overview
Company description
- Provider of nature-derived psilocybin-based psychedelic medicines focused on mental health disorders in palliative care. Conducts Phase IIb clinical trials of natural psilocybin for Adjustment Disorder with psychotherapy and varied dosages, and plans a clinical trial for Alcohol Use Disorder with a focus on Substance Use Disorders.
Products and services
- Phase IIb Clinical Trials: Psyence Biomedical evaluates nature-derived psilocybin for Adjustment Disorder in palliative care, integrating psychotherapy and varied dosing to assess efficacy and patient outcomes
- Nature-Derived Psilocybin-Based Medicines: Engineers psilocybin psychedelic medicines derived from natural sources, focused on mental health disorders within palliative care settings
- Nature-Derived Psilocybin for Alcohol Use Disorder: Plans a clinical trial evaluating natural-source psilocybin efficacy for Alcohol Use Disorder, emphasizing application to Substance Use Disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Psyence Biomed
XenoPort
HQ: United States
Website
- Description: Provider of biopharmaceutical products focused on developing and commercializing internally discovered product candidates for the potential treatment of neurological disorders, including Horizant (gabapentin enacarbil) Extended-Release Tablets, approved and marketed in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XenoPort company profile →
Reunion Neuroscience
HQ: Canada
Website
- Description: Provider of clinical-stage therapeutic solutions for underserved mental health conditions, developing RE104, a proprietary short-duration serotonergic psychedelic therapy for postpartum depression and other mental health disorders, and RE200s, discovery candidates structurally similar to classic psychedelics designed to selectively target the serotonin 2A receptor without off-target effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reunion Neuroscience company profile →
Balance Therapeutics
HQ: United States
Website
- Description: Provider of research and development focused on developing therapeutics to address conditions of intellectual disability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Balance Therapeutics company profile →
Emboline
HQ: United States
Website
- Description: Provider of total embolic protection during percutaneous heart valve repair, offering the Emboliner Total Embolic Protection Catheter designed to capture and remove embolic debris to protect the brain and other organs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emboline company profile →
Neos Therapeutics
HQ: United States
Website
- Description: Provider of oral drug delivery solutions developing controlled time-release technologies, offering CNS stimulants for ADHD (ADZENYS XR-ODT; COTEMPLA XR-ODT), Karbinal ER for allergic conditions, prescription fluoride supplements (Poly-Vi-Flor, Tri-Vi-Flor), the RxConnect patient access program, and AR101 (enzastaurin), a therapeutic candidate for vascular Ehlers-Danlos Syndrome (VEDS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Psyence Biomed
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Psyence Biomed
2.2 - Growth funds investing in similar companies to Psyence Biomed
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Psyence Biomed
4.2 - Public trading comparable groups for Psyence Biomed
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →